Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Achilles Therapeutics plc ACHL

Healthcare Biotechnology
Achilles Therapeutics plc is a United Kingdom-based clinical-stage immuno-oncology biopharmaceutical company. The Company is engaged in developing precision T cell therapies to treat multiple types of solid tumors. Its lead product is a precision tumor-derived T cell therapy targeting clonal cancer neoantigens. Its pipeline includes Chiron: Advanced Non-Small Cell Lung Cancer, Thetis: Melanoma ... see more

Recent & Breaking News (NDAQ:ACHL)

Achilles Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Business Highlights

GlobeNewswire March 1, 2022

Achilles Therapeutics Strengthens Scientific Advisory Board with Appointment of Alena Gros, Ph.D. and Ben Creelan, M.D.

GlobeNewswire February 7, 2022

Achilles Therapeutics Provides Business Update and Outlook for 2022

GlobeNewswire January 13, 2022

Achilles Therapeutics to present at the 40th Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 21, 2021

Achilles Therapeutics Added to the NASDAQ Biotechnology Index

GlobeNewswire December 20, 2021

Achilles Therapeutics Presents Positive Data at ESMO I-O Congress 2021 on High-Dose Manufacturing Process for Precision T Cell Therapies Targeting Clonal Neoantigens

GlobeNewswire December 9, 2021

Achilles Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Demonstrating the Ability to Detect, Quantify and Track Patient-specific cNeT and Significant Increase in cNeT Dose from VELOS(TM) Process 2 Manufacturing

GlobeNewswire November 12, 2021

Secarna Pharmaceuticals and Achilles Therapeutics Sign Research, Option and License Agreement to Develop Optimized T Cell Therapies

Accesswire November 10, 2021

Achilles Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights

GlobeNewswire November 9, 2021

Achilles Therapeutics Presents Data at the 2021 European Society for Gene and Cell Therapy (ESGCT) Congress Demonstrating its Proprietary Manufacturing Process Can Generate Potent, Personalized Anti-Cancer Cell Therapy Candidates in Multiple Solid Tumor Types

GlobeNewswire October 22, 2021

Achilles Therapeutics to join the Northern Alliance Advanced Therapy Treatment Centre consortium

GlobeNewswire October 12, 2021

Achilles Therapeutics to Present at Upcoming Scientific Congresses

GlobeNewswire October 1, 2021

Achilles Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire September 2, 2021

Achilles Therapeutics Announces Grant of US and European Patents

GlobeNewswire August 25, 2021

Achilles Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights

GlobeNewswire August 10, 2021

Achilles Therapeutics Enrolls First US Patient in Ongoing Phase I/IIa Study in Advanced Non-small Cell Lung Cancer

GlobeNewswire July 1, 2021

Achilles Therapeutics Details Phase I/IIa Clinical Trial Design of CHIRON in Patients with Advanced Non-Small Cell Lung Cancer at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire June 4, 2021

Achilles Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Highlights

GlobeNewswire May 11, 2021

Achilles Therapeutics Receives Horizon 2020 Grant as Part of Neoantigen Consortium

GlobeNewswire May 6, 2021

Achilles Therapeutics to present at the BofA Securities 2021 Virtual Healthcare Conference

GlobeNewswire May 5, 2021